A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
- Sponsor:
- ECOG-ACRIN Cancer Research Group
- Sponsor Study ID:
- EA5221
- CTO #:
- 104067
- NCT Number:
- NCT06096844
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- To evaluate whether there is an improvement in overall survival (OS) with chemotherapy combined with pembrolizumab compared to single agent pembrolizumab in this vulnerable older adult patient population.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Affiliate Principal Investigator, Lupak, Oleksandra, at oll203@musc.edu .
- Principal Investigator, Rangel, Christopher, at rangelc@musc.edu .
- Study Coordinator, Schumpp, Alec, at schumpp@musc.edu .
-
Ralph H. Johnson VAMC
- Study Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov .
Trial opened at the following institutions:
Ralph H. Johnson VAMC, Medical University of South Carolina